Oncolytic Viruses as In Situ Cancer Vaccines: Tumor Microenvironment Remodeling, Checkpoint Inhibitor Synergy, and Biomarker-Guided Clinical Translation
Oncolytic viruses (OVs) are increasingly viewed not only as tumor-lysing agents but also as immunotherapeutic platforms capable of functioning as in situ cancer vaccines. By selectively infecting malignant cells, inducing immunogenic cell death, releasing tumor-associated antigens and danger signals, and activating inn...